קימריה ישראל - עברית - Ministry of Health

קימריה

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

אבילק סירופ ישראל - עברית - Ministry of Health

אבילק סירופ

padagis israel pharmaceuticals ltd, israel - lactulose - סירופ - lactulose 66.7 g / 100 ml - lactulose - lactulose - constipation. acute and chronic hepatic encephalopathy.

לשקוטאן משחה ישראל - עברית - Ministry of Health

לשקוטאן משחה

teva israel ltd - methylbenzethonium chloride; paromomycin as sulfate - משחה - methylbenzethonium chloride 12 %w/w; paromomycin as sulfate 15 %w/w - paromomycin - paromomycin - topical treatment of cutaneous leishmaniasis.

יוקריאס 50/850 מ"ג ישראל - עברית - Ministry of Health

יוקריאס 50/850 מ"ג

novartis pharma services ag - metformin hydrochloride 850 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:• eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

יוקריאס 50/500 מ"ג ישראל - עברית - Ministry of Health

יוקריאס 50/500 מ"ג

novartis pharma services ag - metformin hydrochloride 500 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.

קומפטקט 15 מג  850 מג ישראל - עברית - Ministry of Health

קומפטקט 15 מג 850 מג

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

בייאטה 5 מק"ג ישראל - עברית - Ministry of Health

בייאטה 5 מק"ג

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

בייאטה 5 מק"ג ישראל - עברית - Ministry of Health

בייאטה 5 מק"ג

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

בייאטה 10 מק"ג ישראל - עברית - Ministry of Health

בייאטה 10 מק"ג

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

בייאטה 10 מק"ג ישראל - עברית - Ministry of Health

בייאטה 10 מק"ג

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.